Biopharmaceutical Excipient Manufacturing

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured during our research. It offers a high-level view on the likely evolution of the biopharmaceutical excipient manufacturing market in the short to mid-term, and long term.

Chapter 3 provides a general overview of the biopharmaceutical excipients. In addition, it includes information on their properties and classification, based on route of administration, chemical structure, function, ability to interfere with metabolization and efflux mechanisms. Further, it highlights various applications of biopharmaceutical excipients and their role in pharmaceutical and biopharmaceutical industry. 

Chapter 4 provides an overview of the current biopharmaceutical excipients, along with information on their year of establishment, company size (in terms of employee count), location of headquarters, location of manufacturing facilities, type of excipient (based on chemical composition (carbohydrates, polyols, polymers, proteins / amino acids, salts, lipids, and others), based on function (surfactants, stabilizers, tonicity modifiers, bulking agents, buffering agents, solubility enhancers, drug delivery system, chelators, antimicrobials, antioxidants and others), based on chemical structure (organic and inorganic)), scale of operation (preclinical, clinical and commercial),  type of formulation (liquid or parenteral and solid), type of biologic (vaccines, proteins / peptides, cell therapies, antibodies and blood products) and global regulatory compliance (United States Pharmacopoeia / United States Pharmacopoeia-National Formulary, European Pharmacopoeia, Japanese Pharmacopoeia, British Pharmacopoeia, China Pharmacopoeia, American Chemical Society grade, Indian Pharmacopoeia, Food Chemical Codex and Taiwan FDA).

Chapter 5 features a detailed competitiveness analysis of the biopharmaceutical excipient manufacturers, based on supplier power (in terms of years of experience), company competitiveness (type of excipient based on chemical composition, function, chemical structure, and based on scale of operation, type of formulation, type of biologic, global regulatory compliance) and number of manufacturing facilities.

Chapter 6 provides detailed profiles of prominent players (shortlisted based on a proprietary criterion) engaged in this domain. Each profile features a brief overview of the company (including information on year of establishment, number of employees, location of headquarters and key executives), financial information (if available), details related to its biopharmaceutical excipients portfolio, manufacturing facilities, recent developments, and an informed future outlook. 

Chapter 7 features an analysis of the various collaborations and partnerships inked between stakeholders engaged in this domain, during the period 2016-2021, covering distribution agreements, acquisitions, supply agreements, product development agreements, asset acquisitions, research and development agreements, manufacturing agreements, service alliances and other related agreements.

Chapter 8 presents a detailed analysis of the recent expansions undertaken by various biopharmaceutical excipient manufacturers, based on several relevant parameters, such as year of expansion, type of expansion (capacity expansion, facility expansion and new facility), company size (small, mid-sized, large and very large companies), location of headquarters, location of expanded facility, type of excipient, type of drug molecule, most active players (in terms of number of recent expansions) and geographical distribution (region-wise and country-wise).

Chapter 9 features a comprehensive analysis of the global installed capacity for biopharmaceutical excipients taking into consideration the capacities of various biopharmaceutical excipient manufacturers, along with information on the distribution of available global biopharmaceutical excipient production capacity based on several relevant parameters, such as company size (small, mid-sized, large and very large companies), scale of operation (preclinical, clinical and commercial) and key geographical regions (North America, Europe, and Asia-Pacific).

Chapter 10 presents an insightful market forecast analysis, highlighting the likely growth of the biopharmaceutical excipient manufacturing market till the year 2035. In order to provide details on the future opportunity, our projections have been segmented on the basis of [A] type of biologic (antibodies, vaccines, cell therapies and other biologics), [B] type of excipient (carbohydrates, polymers, solubilizers / surfactants, polyols, proteins / amino acids and others), [C] company size (small, mid-sized, large / very large), [D] scale of operation (preclinical, clinical and commercial) and [E] key geographical regions (North America, Europe, Asia-Pacific, Latin America, MENA and rest of the world).

Chapter 11 summarizes the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 12 provides the transcripts of interviews conducted with representatives from renowned organizations that are engaged in the biopharmaceutical excipient manufacturing domain. 

Chapter 13 is an appendix, that provides tabulated data and numbers for all the figures included in the report.

Chapter 14 is an appendix that provides the list of companies and organizations that have been mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Biopharmaceutical Excipients
3.3. Properties of Ideal Excipients
3.4. Classification of Biopharmaceutical Excipients
3.4.1. Classification based on Route of Administration
3.4.2. Classification of Excipients based on Structure
3.4.3. Classification of Excipients based on Function
3.4.4. Classification based on Ability to Interfere with Metabolization and Efflux Mechanisms

3.5. Applications of Biopharmaceutical Excipients
3.6. Regulatory Scenario
3.7. Concluding Remarks

4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Biopharmaceutical Excipient Manufacturers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Location of Biopharmaceutical Excipient Manufacturing Facilities
4.2.5. Analysis by Type of Excipient based on Chemical Composition
4.2.6. Analysis by Type of Excipient based on Function
4.2.7. Analysis by Type of Excipient based on Chemical Structure
4.2.8. Analysis by Scale of Operation
4.2.9. Analysis by Type of Formulation
4.2.10. Analysis by Type of Biologic
4.2.11. Analysis by Global Regulatory Compliance

5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Assumptions and Key Parameters
5.3. Methodology
5.4. Biopharmaceutical Excipient Manufacturers: Company Competitiveness Analysis
5.4.1. Company Competitiveness Analysis: Small Companies
5.4.2. Company Competitiveness Analysis: Mid-Sized Companies
5.4.3. Company Competitiveness Analysis: Large Companies
5.4.4. Company Competitiveness Analysis: Very Large Companies

6. COMPANY PROFILES: BIOPHARMACEUTICAL EXCIPIENT MANUFACTURERS
6.1. Chapter Overview
6.2. ABITEC
6.2.1. Company Overview
6.2.2. Biopharmaceutical Excipient Offerings
6.2.3. Manufacturing Facilities
6.2.4. Recent Developments and Future Outlook

6.3. Avantor
6.3.1. Company Overview
6.3.2. Financial Information
6.3.3. Biopharmaceutical Excipient Offerings
6.3.4. Manufacturing Facilities
6.3.5. Recent Developments and Future Outlook

6.4. BASF Pharma
6.4.1. Company Overview
6.4.2. Financial Information
6.4.3. Biopharmaceutical Excipient Offerings
6.4.4. Manufacturing Facilities
6.4.5. Recent Developments and Future Outlook

6.5. Corden Pharma
6.5.1. Company Overview
6.5.2. Biopharmaceutical Excipient Service Offerings
6.5.3. Manufacturing Facilities
6.5.4. Recent Developments and Future Outlook

6.6. DFE Pharma
6.6.1. Company Overview
6.6.2. Biopharmaceutical Excipient Offerings
6.6.3. Manufacturing Facilities
6.6.4. Recent Developments and Future Outlook

6.7. Evonik
6.7.1. Company Overview
6.7.2. Financial Information
6.7.3. Biopharmaceutical Excipient Offerings
6.7.4. Manufacturing Facilities
6.7.5. Recent Developments and Future Outlook

6.8. Kirsch Pharma
6.8.1. Company Overview
6.8.2. Biopharmaceutical Excipient Offerings
6.8.3. Manufacturing Facilities
6.8.4. Recent Developments and Future Outlook

6.9. Merck KGaA
6.9.1. Company Overview
6.9.2. Financial Information
6.9.3. Biopharmaceutical Excipient Offerings
6.9.4. Manufacturing Facilities
6.9.5. Recent Developments and Future Outlook

6.10. Pfanstiehl
6.10.1. Company Overview
6.10.2. Biopharmaceutical Excipient Offerings
6.10.3. Manufacturing Facilities
6.10.4. Recent Developments and Future Outlook

6.11. Roquette
6.11.1. Company Overview
6.11.2. Biopharmaceutical Excipient Offerings
6.11.3. Manufacturing Facilities
6.11.4. Recent Developments and Future Outlook

6.12. Spectrum Chemical Manufacturing
6.12.1. Company Overview
6.12.2. Biopharmaceutical Excipient Offerings
6.12.3. Manufacturing Facilities
6.12.4. Recent Developments and Future Outlook

6.13. SPI Pharma
6.13.1. Company Overview
6.13.2. Biopharmaceutical Excipient Offerings
6.13.3. Manufacturing Facilities
6.13.4. Recent Developments and Future Outlook

7. PARTNERSHIPS AND COLLABORATIONS
7.1. Chapter Overview
7.2. Partnership Models
7.3. Biopharmaceutical Excipients Manufacturing Market: Partnerships and Collaborations
7.3.1. Analysis by Year of Partnership
7.3.2. Analysis by Type of Partnership
7.3.3. Analysis by Year and Type of Partnership
7.3.4. Analysis by Type of Excipient
7.3.5. Analysis by Type of Drug Molecule
7.3.5. Most Active Players: Analysis by Number of Partnerships
7.3.6. Analysis by Geography
7.3.6.1. Intercontinental and Intracontinental Deals
7.3.6.2. International and Local Deals

8. RECENT EXPANSIONS
8.1. Chapter Overview
8.2. Biopharmaceutical Excipient Manufacturing Market: Recent Expansions
8.2.1. Analysis by Year of Expansion
8.2.2. Analysis by Type of Expansion
8.2.3. Analysis by Company Size and Location of Headquarters
8.2.4. Analysis by Location of Expanded Facility
8.2.5. Analysis by Type of Excipient
8.2.6. Analysis by Type of Drug Molecule
8.2.7. Most Active Players: Analysis by Number of Recent Expansions
8.2.8. Geographical Analysis
8.2.8.1. Region-wise Distribution
8.2.8.2. Country-wise Distribution

9. CAPACITY ANALYSIS
9.1. Chapter Overview
9.2. Key Assumptions and Methodology
9.3. Biopharmaceutical Excipient Manufacturing: Installed Global Capacity
9.3.1. Analysis by Company Size
9.3.2. Analysis by Scale of Operation
9.3.3. Analysis by Location of Manufacturing Facility
9.4. Concluding Remarks

10. MARKET FORECAST AND OPPORTUNITY ANALYSIS
10.1. Chapter Overview
10.2. Forecast Methodology and Key Assumptions
10.3. Global Biopharmaceutical Excipient Manufacturing Market, 2022-2035
10.4. Biopharmaceutical Excipient Manufacturing Market: Distribution by Type of Biologic, 2022 and 2035
10.5. Biopharmaceutical Excipient Manufacturing Market: Distribution by Type of Excipient, 2022 and 2035
10.6. Biopharmaceutical Excipient Manufacturing Market: Distribution by Company Size, 2022 and 2035
10.7. Biopharmaceutical Excipient Manufacturing Market: Distribution by Scale of Operation, 2022 and 2035
10.8. Biopharmaceutical Excipient Manufacturing Market: Distribution by Region, 2022 and 2035
10.8.1. Biopharmaceutical Excipient Manufacturing Market in North America, 2022-2035
10.8.2. Biopharmaceutical Excipient Manufacturing Market in Europe, 2022-2035
10.8.3. Biopharmaceutical Excipient Manufacturing Market in Asia Pacific, 2022-2035
10.8.4. Biopharmaceutical Excipient Manufacturing Market in Latin America, 2022-2035
10.8.5. Biopharmaceutical Excipient Manufacturing Market in MENA, 2022-2035
10.8.6. Biopharmaceutical Excipient Manufacturing Market in Rest of the World, 2022-2035

11. CONCLUDING REMARKS

12. EXECUTIVE INSIGHTS
12.1. Chapter Overview
12.2. DFE Pharma
12.2.1. Company Snapshot
12.2.2. Interview Transcript: Jeannette M. Wetzel, Biopharma Sales Director

13. APPENDIX 1: TABULATED DATA

14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1 Executive Summary: Market Forecast
Figure 2.1 Executive Summary: Overall Market Landscape
Figure 2.2 Executive Summary: Partnerships and Collaborations
Figure 2.3 Executive Summary: Recent Expansions
Figure 2.4 Executive Summary: Capacity Analysis
Figure 2.5 Executive Summary: Market Forecast
Figure 3.1 Properties of an Ideal Excipient
Figure 3.2 Classification of Biopharmaceutical Excipients based on Ability to Interfere with Metabolization and Efflux Mechanisms
Figure 3.3 Applications of Biopharmaceutical Excipients
Figure 4.1 Biopharmaceutical Excipient Manufacturers: Distribution by Year of Establishment
Figure 4.2 Biopharmaceutical Excipient Manufacturers: Distribution by Company Size
Figure 4.3 Biopharmaceutical Excipient Manufacturers: Distribution by Location of Headquarters (Region-wise)
Figure 4.4 Biopharmaceutical Excipient Manufacturers: Distribution by Location of Headquarters (Country-wise)
Figure 4.5 Biopharmaceutical Excipient Manufacturers: Distribution by Location of Headquarters and Company Size
Figure 4.6 Biopharmaceutical Excipient Manufacturers: Distribution by Location of Biopharmaceutical Excipient Manufacturing Facilities (Region-wise)
Figure 4.7 Biopharmaceutical Excipients Manufacturers: Distribution by Location of Biopharmaceutical Excipient Manufacturing Facilities (Country-wise)
Figure 4.8 Biopharmaceutical Excipient Manufacturers: Distribution by Type of Excipient based on Chemical Composition
Figure 4.9 Biopharmaceutical Excipient Manufacturers: Distribution by Type of Excipient based on Function
Figure 4.10 Biopharmaceutical Excipient Manufacturers: Distribution by Type of Excipient based on Chemical Structure
Figure 4.11 Biopharmaceutical Excipient Manufacturers: Distribution by Scale of Operation
Figure 4.12 Biopharmaceutical Excipient Manufacturers: Distribution by Type of Formulation
Figure 4.13 Biopharmaceutical Excipient Manufacturers: Distribution by Type of Biologic
Figure 4.14 Biopharmaceutical Excipient Manufacturers: Distribution by Global Regulatory Compliance
Figure 5.1 Company Competitiveness Analysis: Small Companies
Figure 5.2 Company Competitiveness Analysis: Mid-sized Companies
Figure 5.3 Company Competitiveness Analysis: Large Companies
Figure 5.4 Company Competitiveness Analysis: Very Large Companies
Figure 6.1 BASF Pharma: Annual Revenues, 2016-2021 (EUR Million)
Figure 6.2 Evonik: Annual Revenues, 2016-2020 (EUR Million)
Figure 6.3 Merck KGaA: Annual Revenues, 2016-2021 (EUR Million)
Figure 7.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2016-2021
Figure 7.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 7.3 Partnerships and Collaborations: Year-wise Trend by Type of Partnership
Figure 7.4 Partnerships and Collaborations: Distribution by Type of Excipient
Figure 7.5 Partnerships and Collaborations: Distribution by Type of Drug Molecule
Figure 7.6 Partnerships and Collaborations: Year-Wise Trend of Partnerships by Type of Drug Molecule, 2016-2021
Figure 7.7 Most Active Players: Distribution by Number of Partnerships
Figure 7.8 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Figure 7.9 Partnerships and Collaborations: International and Local Distribution
Figure 8.1 Recent Expansions: Cumulative Year-wise Trend, 2016-2021
Figure 8.2 Recent Expansions: Distribution by Type of Expansion
Figure 8.3 Recent Expansions: Distribution by Company Size and Location of Headquarters
Figure 8.4 Recent Expansions: Distribution by Location of Expanded Facility
Figure 8.5 Recent Expansions: Distribution by Location of Facility Expanded and Type of Expansion
Figure 8.6 Recent Expansions: Distribution by Type of Excipient
Figure 8.7 Recent Expansions: Distribution by Type of Drug Molecule
Figure 8.8 Most Active Players: Distribution by Number of Recent Expansions
Figure 8.9 Recent Expansions: Year-wise Distribution by Geography
Figure 8.10 Recent Expansions: Country-wise Distribution
Figure 9.1 Biopharmaceutical Excipient Manufacturing Installed Global Capacity: Distribution by Range of Installed Capacity
Figure 9.2 Biopharmaceutical Excipient Manufacturing Installed Global Capacity: Distribution by Company Size
Figure 9.3 Biopharmaceutical Excipient Manufacturing Installed Global Capacity: Distribution by Scale of Operation
Figure 9.4 Biopharmaceutical Excipient Manufacturing Installed Global Capacity: Distribution by Location of Manufacturing Facility (Continent-wise)
Figure 9.5 Biopharmaceutical Excipient Manufacturing Installed Global Capacity: Distribution by Location of Manufacturing Facility (Country-wise)
Figure 10.1 Global Biopharmaceutical Excipient Manufacturing Market, 2022-2035 (USD Billion)
Figure 10.2 Biopharmaceutical Excipient Manufacturing Market: Likely Growth Scenarios
Figure 10.3 Biopharmaceutical Excipient Manufacturing Market: Distribution by Type of Biologic, 2022 and 2035 (USD Billion)
Figure 10.4 Biopharmaceutical Excipient Manufacturing Market: Distribution by Type of Excipient, 2022 and 2035 (USD Billion)
Figure 10.5 Biopharmaceutical Excipient Manufacturing Market: Distribution by Company Size, 2022 and 2035 (USD Billion)
Figure 10.6 Biopharmaceutical Excipient Manufacturing Market: Distribution by Scale of Operation, 2022 and 2035 (USD Billion)
Figure 10.7 Biopharmaceutical Excipient Manufacturing Market: Distribution by Region, 2022 and 2035(USD Billion)
Figure 10.8 Biopharmaceutical Excipient Manufacturing Market in North America, 2022-2035 (USD Billion)
Figure 10.9 Biopharmaceutical Excipient Manufacturing Market in Europe, 2022-2035 (USD Billion)
Figure 10.10 Biopharmaceutical Excipient Manufacturing Market in Asia Pacific, 2022-2035 (USD Billion)
Figure 10.11 Biopharmaceutical Excipient Manufacturing Market in Latin America, 2022-2035 (USD Billion)
Figure 10.12 Biopharmaceutical Excipient Manufacturing Market in MENA, 2022-2035 (USD Billion)
Figure 10.13 Biopharmaceutical Excipient Manufacturing Market in Rest of the World, 2022-2035 (USD Billion)
Figure 11.1 Concluding Remarks: Overall Market Landscape
Figure 11.2 Concluding Remarks: Partnerships and Collaborations
Figure 11.3 Concluding Remarks: Recent Expansions
Figure 11.4 Concluding Remarks: Capacity Analysis
Figure 11.5 Concluding Remarks: Market Forecast

List Of Tables

Table 3.1 Classification of Biopharmaceutical Excipients based on Function
Table 4.1 Biopharmaceutical Excipient Manufacturers: List of Companies
Table 4.2 Biopharmaceutical Excipient Manufacturers: Information on Type of Excipient based on Chemical Composition and Function
Table 4.3 Biopharmaceutical Excipient Manufacturers: Information on Scale of Operation, Type of Formulation, Type of Excipient (based on Chemical Structure), Type of Biologic and Global Regulatory Compliance
Table 6.1 Leading Biopharmaceutical Excipient Manufacturers
Table 6.2 ABITEC: Company Snapshot
Table 6.3 ABITEC: Biopharmaceutical Excipient Offerings
Table 6.4 ABITEC: Information on Manufacturing Facilities
Table 6.5 ABITEC: Recent Developments and Future Outlook
Table 6.6 Avantor: Company Snapshot
Table 6.7 Avantor: Biopharmaceutical Excipient Offerings
Table 6.8 Avantor: Information on Manufacturing Facilities
Table 6.9 Avantor: Recent Developments and Future Outlook
Table 6.10 BASF: Company Snapshot
Table 6.11 BASF: Biopharmaceutical Excipient Offerings
Table 6.12 BASF: Information on Manufacturing Facilities
Table 6.13 BASF: Recent Developments and Future Outlook
Table 6.14 Corden Pharma: Company Snapshot
Table 6.15 Corden Pharma: Biopharmaceutical Excipient Offerings
Table 6.16 Corden Pharma: Information on Manufacturing Facilities
Table 6.17 Corden Pharma: Recent Developments and Future Outlook
Table 6.18 DFE Pharma: Company Snapshot
Table 6.19 DFE Pharma: Biopharmaceutical Excipient Offerings
Table 6.20 DFE Pharma: Information on Manufacturing Facilities
Table 6.21 DFE Pharma: Recent Developments and Future Outlook
Table 6.22 Evonik: Company Snapshot
Table 6.23 Evonik: Biopharmaceutical Excipient Offerings
Table 6.24 Evonik: Information on Manufacturing Facilities
Table 6.25 Evonik: Recent Developments and Future Outlook
Table 6.26 Kirsch Pharma: Company Snapshot
Table 6.27 Kirsch Pharma: Biopharmaceutical Excipient Offerings
Table 6.28 Kirsch Pharma: Information on Manufacturing Facilities
Table 6.29 Kirsch Pharma: Recent Developments and Future Outlook
Table 6.30 Merck KGaA: Company Snapshot
Table 6.31 Merck KGaA: Biopharmaceutical Excipient Offerings
Table 6.32 Merck KGaA: Information on Manufacturing Facilities
Table 6.33 Merck KGaA: Recent Developments and Future Outlook
Table 6.34 Pfanstiehl: Company Snapshot
Table 6.35 Pfanstiehl: Biopharmaceutical Excipient Offerings
Table 6.36 Pfanstiehl: Information on Manufacturing Facilities
Table 6.37 Pfanstiehl: Recent Developments and Future Outlook
Table 6.38 Roquette: Company Snapshot
Table 6.39 Roquette: Biopharmaceutical Excipient Offerings
Table 6.40 Roquette: Information on Manufacturing Facilities
Table 6.41 Roquette: Recent Developments and Future Outlook
Table 6.42 Spectrum Chemical Manufacturing: Company Snapshot
Table 6.43 Spectrum Chemical Manufacturing: Biopharmaceutical Excipient Offerings
Table 6.44 Spectrum Chemical Manufacturing: Information on Manufacturing Facilities
Table 6.45 SPI Pharma: Company Snapshot
Table 6.46 SPI Pharma: Biopharmaceutical Excipient Offerings
Table 6.47 SPI Pharma: Information on Manufacturing Facilities
Table 6.48 SPI Pharma: Recent Developments and Future Outlook
Table 7.1 Biopharmaceutical Excipient Manufacturers: List of Partnerships and Collaborations, 2016-2021
Table 8.1 Biopharmaceutical Excipient Manufacturers: Recent Expansions, 2016-2021
Table 9.1 Capacity Analysis: Information on Company Size of Biopharmaceutical Excipient Manufacturers
Table 9.2 Capacity Analysis: Information on Average Capacity by Company Size
Table 9.3 Biopharmaceutical Excipient Manufacturing Installed Global Capacity: Total Capacity by Company Size
Table 12.1 DFE Pharma: Company Snapshot
Table 13.1 Biopharmaceutical Excipient Manufacturers: Distribution by Year of Establishment
Table 13.2 Biopharmaceutical Excipient Manufacturers: Distribution by Company Size
Table 13.3 Biopharmaceutical Excipient Manufacturers: Distribution by Location of Headquarters (Region-wise)
Table 13.4 Biopharmaceutical Excipient Manufacturers: Distribution by Location of Headquarters (Country-wise)
Table 13.5 Biopharmaceutical Excipient Manufacturers: Distribution by Location of Headquarters and Company Size
Table 13.6 Biopharmaceutical Excipient Manufacturers: Distribution by Location of Biopharmaceutical Excipient Manufacturing Facilities (Region-wise)
Table 13.7 Biopharmaceutical Excipients Manufacturers: Distribution by Location of Biopharmaceutical Excipient Manufacturing Facilities (Country-wise)
Table 13.8 Biopharmaceutical Excipient Manufacturers: Distribution by Type of Excipient based on Chemical Composition
Table 13.9 Biopharmaceutical Excipient Manufacturers: Distribution by Type of Excipient based on Function
Table 13.10 Biopharmaceutical Excipient Manufacturers: Distribution by Type of Excipient based on Chemical Structure
Table 13.11 Biopharmaceutical Excipient Manufacturers: Distribution by Scale of Operation
Table 13.12 Biopharmaceutical Excipient Manufacturers: Distribution by Type of Formulation
Table 13.13 Biopharmaceutical Excipient Manufacturers: Distribution by Type of Biologic
Table 13.14 Biopharmaceutical Excipient Manufacturers: Distribution by Global Regulatory Compliance
Table 13.15 BASF Pharma: Annual Revenues, 2016-2021 (EUR Million)
Table 13.16 Evonik: Annual Revenues, 2016-2020 (EUR Million)
Table 13.17 Merck KGaA: Annual Revenues, 2016-2021 (EUR Million)
Table 13.18 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2016-2021
Table 13.19 Partnerships and Collaborations: Distribution by Type of Partnership
Table 13.20 Partnerships and Collaborations: Year-wise Trend by Type of Partnership
Table 13.21 Partnerships and Collaborations: Distribution by Type of Excipient
Table 13.22 Partnerships and Collaborations: Distribution by Type of Drug Molecule
Table 13.23 Partnerships and Collaborations: Year-Wise Trend of Partnerships by Type of Drug Molecule, 2016-2021
Table 13.24 Most Active Players: Distribution by Number of Partnerships
Table 13.25 Partnerships and Collaborations: Distribution by Intercontinental and Intracontinental Deals
Table 13.26 Partnerships and Collaborations: Distribution by International and Local Deals
Table 13.27 Recent Expansions: Cumulative Year-wise Trend, 2016-2021
Table 13.28 Recent Expansions: Distribution by Type of Expansion
Table 13.29 Recent Expansions: Distribution by Company Size and Location of Headquarters
Table 13.30 Recent Expansions: Distribution by Location of Expanded Facility
Table 13.31 Recent Expansions: Distribution by Location of Facility Expanded and Type of Expansion
Table 13.32 Recent Expansions: Distribution by Type of Excipient
Table 13.33 Recent Expansions: Distribution by Type of Drug Molecule
Table 13.34 Most Active Players: Distribution by Number of Recent Expansions
Table 13.35 Recent Expansions: Year-wise Distribution by Geography
Table 13.36 Recent Expansions: Country-wise Distribution
Table 13.37 Biopharmaceutical Excipient Manufacturing Installed Global Capacity: Distribution by Range of Installed Capacity
Table 13.38 Biopharmaceutical Excipient Manufacturing Installed Global Capacity: Distribution by Company Size
Table 13.39 Biopharmaceutical Excipient Manufacturing Installed Global Capacity: Distribution by Scale of Operation
Table 13.40 Biopharmaceutical Excipient Manufacturing Installed Global Capacity: Distribution by Location of Manufacturing Facility (Continent-wise)
Table 13.41 Biopharmaceutical Excipient Manufacturing Installed Global Capacity: Distribution by Location of Manufacturing Facility (Country-wise)
Table 13.42 Global Biopharmaceutical Excipient Manufacturing Market, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 13.43 Biopharmaceutical Excipient Manufacturing Market: Distribution by Type of Biologic, 2022 and 2035 (USD Billion)
Table 13.44 Biopharmaceutical Excipient Manufacturing Market: Distribution by Type of Excipient, 2022 and 2035 (USD Billion)
Table 13.45 Biopharmaceutical Excipient Manufacturing Market: Distribution by Company Size, 2022 and 2035 (USD Billion)
Table 13.46 Biopharmaceutical Excipient Manufacturing Market: Distribution by Scale of Operation, 2022 and 2035 (USD Billion)
Table 13.47 Biopharmaceutical Excipient Manufacturing Market: Distribution by Region, Conservative, Base and Optimistic Scenarios, 2022 and 2035 (USD Billion)
Table 13.48 Biopharmaceutical Excipient Manufacturing Market in North America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 13.49 Biopharmaceutical Excipient Manufacturing Market in Europe, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 13.50 Biopharmaceutical Excipient Manufacturing Market in Asia Pacific, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 13.51 Biopharmaceutical Excipient Manufacturing Market in Latin America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 13.52 Biopharmaceutical Excipient Manufacturing Market in MENA, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 13.53 Biopharmaceutical Excipient Manufacturing Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

1. A&C
2. ABITEC
3. Aceto
4. Aditya Chemicals
5. Alfa Aesar
6. AMCM
7. AmpTec
8. ANGUS Chemical Company
9. Apothecon Pharmaceuticals
10. Asahi Kasei
11. Avanti Polar Lipids
12. Avantor
13. Azelis Americas
14. Barentz
15. BASF 
16. BioNTech
17. BioSpectra
18. BOC Sciences
19. Brenntag
20. Cascade Chemistry 
21. CG Chemikalien
22. Cole-Parmer
23. CordenPharma
24. CPI
25. Creative Biostructure
26. Crest Cellulose (Acquired by Roquette)
27. Croda
28. DFE Pharma
29. DKSH
30. DuPont
31. DURECT
32. Evonik
33. Finar
34. GELITA
35. Harro Höfliger Verpackungsmaschinen
36. Hawkins
37. Hopax Fine Chemicals
38. Hosokawa Micron Powder Systems
39. Hunan Er-Kang Pharmaceutical
40. IMCD
41. IMCoPharma
42. Indchem International 
43. InnoCore Pharmaceuticals
44. International Flavors & Fragrances 
45. InVitria
46. Itacel (Acquired by Roquette)
47. ITW Reagents (A division of PanReac AppliChem)
48. Kerry
49. Kirsch Pharma
50. Kuraray
51. Larodan
52. Lazuline Biotech
53. LeBaronBrown Specialities
54. LUCA AICell
55. MaaS Pharma Chemicals
56. MEGGLE
57. Merck KGaA
58. Mitushi Biopharma
59. Moderna
60. National Institute of Bioprocessing Research and Training
61. Nordmann, Rassmann
62. PCAS
63. Pfanstiehl
64. Pfizer
65. Quadra Chemicals
66. ReForm Biologics
67. Roquette
68. Shanghai Huamao Pharmaceutical 
69. Sigachi
70. Spectrum Chemical Mfg.
71. SPI Pharma
72. Stanford University
73. TTY Biopharm
74. Univar Solutions
75. VAV Life Sciences
76. Wilshire Technologies